Stocks closed modestly mixed on light volume Friday in the last full trading week of the year, which marked the third week in a row of overall gains. While drugmakers Pfizer and Merck put a damper on the Dow, robust earnings fr…
If the extension of the Bush tax cuts triggers a market rally, as many expect, investors will likely rush in. But caution is advised: High prices can also mean high risk. Here are some tips from Alan Lancz, director of research…
Here’s a roundup of some of Wednesday’s major pharmaceutical news: An FDA panel gave Human Genome Sciences a boost with a thumbs-up for its lupus drug, Benlysta; Merck’s experimental heart drug appears to work well without side…
Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years…
At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention …